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Objectives. To assess the risk of very low birth weight (VLBW) and extremely low birth weight (ELBW) attributable to second
trimester amniocentesis. Methods. Records of 4,877 consecutive amniocentesis, performed between 1997 and 2003, were analyzed.
Only VLBW and ELBW in the study population (exposed) and in the control group (unexposed) were evaluated. Comparisons
were made between the amniocentesis group versus nonexposed. Odds ratios (OR) and 95% conﬁdence intervals (95% CI) were
calculated for VLBW and ELBW classes. Results. In the study population, the VLBW were 35 (0.71%) and the ELBW were 20
(0.41%). In the control group, the VLBW were 220 (0.67%) and the ELBW were 112 (0.34%). The Odds ratios of the VLBW
between the study and the control group did not show any statistical signiﬁcant risk (OR = 1.07, 95% CI = 0.72–1.54). Also in
ELBW odds ratios between study and control group were not statistically signiﬁcant (OR = 1.20, 95% CI = 0.7–1.95). Conclusions.
No eﬀect of the second trimester amniocentesis was noted on VLBW and ELBW.
1.Introduction
Amniocentesisisaninvasiveprenataldiagnosticexamination
widely performed to screen fetal karyotypic abnormalities
earlyinthesecondtrimesterofpregnancy.Despitetheadvent
of the 1st trimester screening procedures for chromosomal
aneuploidies, there is a growing number of procedures
performedworldwide:inItaly,thenumberofprocedureshas
raised from 50,527 in 1995 up to 101,750 in 2007 [1, 2].
Several studies have attempted to estimate the risks
associated with amniocentesis conducted during the second
trimester [3, 4]: most of them analyzed the risk of fetal
loss related to the procedure, whereas only few studies were
published concerning other possible complications, in par-
ticular the association between amniocentesis and preterm
birth [5–7], especially the association between amniocentesis
and ELBW (extremely low birth weight, less than 1000gr)
and VLBW (very low birth weight, less than 1500gr), two
categories of newborns representing approximately 1–1.5%
of all live births, but contributing up to 40–60% of all
neonatal and infant deaths and to 50% of neurological
neonatal handicap [8–12].
The aim of the present study was to investigate whether
amniocentesis performed during the 2nd trimester of preg-
nancy increase the risk of VLBW and ELBW.
2.MaterialandMethods
A total of 5043 women with singleton pregnancies under-
went amniocentesis between 1997 and 2003 by a single oper-
ator; all amniocentesis were performed under ultrasound
guidanceinfetuseswithabiparietaldiameter(BPD)between
30 and 39mm, as previously described [13].
Of these, 50 women (1% of the total) were lost to follow
up and were excluded. Fetal karyotypic abnormalities were
observed in 95 cases (1.9%), and 43 of them decided to
terminate the pregnancy. In addition, 33 pregnancies were
interrupted due to a major malformation. Moreover, also2 ISRN Obstetrics and Gynecology
Table 1: Number of ELBW and VLBW in study population and
in control group. The odds ratio values between the two classes of
weight in the control group and in the study group did not show




N % N %
ELBW 20 0.41 112 0.34 1.20 0.72–1.54
VLBW 35 0.71 220 0.67 1.07 0.70–1.95
Tot. 4877 32987
fetal losses were excluded from the present study: total fetal
loss was 40 (0.81% of the total): 37 (0.76%) cases occurred
before the 28th gestational week and 3 (0.06) cases after the
28th week of pregnancy, as previously published [13].
The clinical charts of the delivery in a total of 4,877
Caucasian women exposed to amniocentesis were reviewed,
and the birth weight was recorded.
The pregnancy outcome wasdetermined by clinical chart
(80% cases) or by telephone interviews to the women (20%
cases). For all the newborn with prematurity, the clinical
chart was examined.
The control group (unexposed to amniocentesis) was
obtained evaluating VLBW and ELBW from 37,642 consecu-
tive caucasian women who delivered in the same period in
our district. The clinical charts were controlled to exclude
women undergoing amniocentesis elsewhere.
Comparisons were made between the amniocentesis
groupversusnonexposed.Infantoutcomesweregivenforthe
population of women giving birth to live infants.
Odds ratios (OR) and 95% conﬁdence intervals (95%
CI) were calculated for VLBW and ELBW classes. The
comparison between our observed cases and the expected
was expressed by the observed/expected rate (O/E rate).
3. Results
Out of 4,877 women undergoing amniocentesis, total VLBW
were 35 (0.71%). Eleven of them were under the 10th centile
and six of them under the 5◦ centile. ELBW were 20 (0.41%).
Six of them were under the 10◦ percentile and three of them
under the 5th centile. In the control group, the VLBW were
220 (0.67%) and the ELBW were 112 (0.34%). The Odds
ratios of the VLBW between the study and the control group
did not show any statistical signiﬁcant risk (OR = 1.07,
95% CI = 0.72–1.54). Also in ELBW the odds ratios between
the study and control groups were not statistically signiﬁcant
(OR = 1.20, 95% CI = 0.7–1.95) (Table 1).
4. Discussion
The present study is the ﬁrst to analyze the risk of having
ELBW and VLBW newborns after amniocentesis performed
in second trimester and shows no statistically signiﬁcant
increase in these two categories of preterm newborns.
The importance of this ﬁndings lies in the severity of
the VLBW newborns contributing to more than 50% of
infantmortalityandto50%ofneurologicalhandicap[9–12],
with a growing evidence that a signiﬁcant number of these
children have learning disability, attentional problems such
as attention deﬁcit hyperactivity disorder (ADHD), and
minor motor problems [9].
Our ﬁndings are in agreement with those reported in
a cohort study published by Tongsong et al. [7], in which
the authors did not ﬁnd statistically signiﬁcant diﬀerences in
fetallossrateandprematuredelivery;Taboretal.[6],intheir
randomized, controlled study, concluded that amniocentesis
is not related to preterm delivery as well. Moreover, the most
recent cohort study, based on data collected between 1991
and 1996 on 71,586 single births, showed that there is not
an increased risk for limb reduction defects, fetal and infant
mortality, prematurity, fetal distress, and low birth weight
[14].
On the contrary, a positive association between preterm
delivery and genetic amniocentesis has been described in
the EUROPOP study Group (2003), a case-control study
madeby10Europeancountriesinwhich,however,apossible
bias could be represented by the additional burden of
complications contributed by four out of the 10 centers,
performing amniocentesis between the 11th–15th week,
when an increased risk of complications is reported [15, 16].
In conclusion, the absence of increased risk of preterm
delivery associated with genetic amniocenteses performed in
the second trimester of pregnancy makes unnecessary the
information about this complication during the preamnio-
centesis counseling.
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